Jay Steven M, Shepherd Benjamin R, Bertram James P, Pober Jordan S, Saltzman W Mark
Yale University, Department of Biomedical Engineering, 55 Prospect St., New Haven, CT 06511, USA.
FASEB J. 2008 Aug;22(8):2949-56. doi: 10.1096/fj.08-108803. Epub 2008 May 1.
Transplantation of Bcl-2-transduced human umbilical vein endothelial cells (ECs) in protein gels into the gastrocnemius muscle improves local reperfusion in immunodeficient mouse hosts with induced hind limb ischemia. We tested the hypothesis that incorporation of local, sustained growth factor delivery could enhance and accelerate this effect. Tissue engineering scaffolds often use synthetic polymers to enable controlled release of proteins, but most synthetic delivery systems have major limitations, most notably hydrophobicity and inefficient protein loading. Here, we report the development of a novel alginate-based delivery system for vascular endothelial growth factor-A(165) (VEGF) that exhibits superior loading efficiency and physical properties to previous systems in vitro. In vivo, VEGF released from alginate microparticles within protein gels was biologically active and, when combined with EC transplantation, led to increased survival of transplanted cells at 28 days. The composite graft described also improved early (14 days) tissue perfusion and late (28 days) muscle myoglobin expression, a sign of recovery from ischemia, compared with EC transplantation and VEGF delivery separately. We conclude that our improved approach to sustained VEGF delivery in tissue engineering is useful in vivo and that the integration of high efficiency protein delivery enhances the therapeutic effect of protein gel-based EC transplantation.
将经Bcl-2转导的人脐静脉内皮细胞(ECs)移植到蛋白凝胶中并植入免疫缺陷小鼠宿主的腓肠肌内,可改善诱导性后肢缺血小鼠的局部再灌注。我们检验了这样一个假设,即加入局部持续生长因子递送可增强并加速这种效应。组织工程支架通常使用合成聚合物来实现蛋白质的控释,但大多数合成递送系统存在重大局限性,最显著的是疏水性和蛋白质负载效率低下。在此,我们报告了一种新型的基于藻酸盐的血管内皮生长因子-A(165)(VEGF)递送系统的开发,该系统在体外表现出比先前系统更高的负载效率和物理性能。在体内,从蛋白凝胶中的藻酸盐微粒释放的VEGF具有生物活性,并且与EC移植相结合时,可使移植细胞在28天时的存活率增加。与单独的EC移植和VEGF递送相比,所述复合移植物还改善了早期(14天)组织灌注和晚期(28天)肌肉肌红蛋白表达,这是缺血恢复的一个迹象。我们得出结论,我们在组织工程中改进的持续VEGF递送方法在体内是有用的,并且高效蛋白质递送的整合增强了基于蛋白凝胶的EC移植的治疗效果。